German drugs and pesticides group Bayer will pay around $1.6 billion to settle the majority of U.S. claims involving the Essure birth-control device.

The U.S. Food and Drug Administration approved a new protocol for a post-marketing study of Bayer AG’s Essure birth-control device, as the regulator seeks more information on the device’s safety.

Bayer AG disputed accusations in a new Netflix documentary that claims medical device makers and the U.S. Food and Drug Administration placed profits before patient safety.